News/Publications/Press

09 July 2019

PIDs included in WHO List of Essential Diagnostic Tests

(from https://ipopi.org/)

 

Primary immunodeficiency (PID) diagnostic tests have been included in the World Health Organization (WHO)’s Essential Diagnostics List (EDL) published by WHO on July 9, 2019.

The second publication of the Model List of Essential In Vitro Diagnostics*, also called Essential Diagnostics List (EDL), now includes a new disease-specific section on primary immunodeficiencies (PIDs) as well as a mention of PIDs, in general, for clinical laboratory diagnosis (for more information see here).

Epimune is dedicated to improving early detection of PID by developing in-vitro diagnostic tests for lymphoycyte enumeration from a drop of (dried) blood. 


20 May 2019

Epimune wins funding from the German Federal Ministry of Education and Research (BMBF) to support R&D of molecular diagnosis and prognosis of Non-Hodgkin Lymphoma  

Together with researchers from the Martin Luther University Halle-Wittenberg,  Epimune will explore application of its proprietary epigenetic immune cell quantification technology for the early diagnosis, prognosis and monitoring of patients with B-cell Non-Hodgkin Lymphoma. The 3-year project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of 925,000 €


01 Apr 2019

Epimune appoints Dr. Uwe Staub as Chief Executive Officer (CEO) 

Dr. Staub has 25 years of experience in the in-vitro diagnostic (IVD) industry. Before joining Epimune, he was part of Epigenomics' executive team, and held senior management positions at Qiagen, Digene and Abbott

Upcoming Events

18-21 Sep 2019

European Society for Immunodeficiencies (ESID) 2019 Focused Meeting (Brussels, BE)

  • Oral presentation (21 Sep 2019; 08:25) -  MOLECULAR DIAGNOSTIC IMMUNE CELL QUANTIFICATION - A NOVEL APPROACH TO IDENTIFY AND MONITOR PATIENTS WITH IMMUNE CELL DYSREGULATION

06-08 Nov 2019

International Primary Immunodeficiency Congress (IPIC) 2019 (Madrid, ES)

  • Epimune will exhibit at the IPIC 2019. Visit us at booth #7 to learn about Epimune's approach to pioneering early detection of PID